Figure 6
Figure 6. MYD88 signals through BTK in response to TLR stimulation, and BTK is stimulated by MYD88 L265P in WM cells. (A) The impacts of TLR4 ligand, LPS, and TLR9 ligand, ODN 2006 (a type B CpG oligonucleotide; InvivoGen), on the phosphorylation of BTK and IκBα in BCWM.1 WM cells in the presence or absence of a MYD88 inhibitor. (B) Total and phospho-BTK levels in WM cells transduced with a lentiviral control vector, or vectors engineered to overexpress flag-tagged MYD88 WT or L265P coding regions. (C) The impact of ibrutinib on the phosphorylation state of BTK and IκBα depicted by western blot analysis. (D) Dose-response curve for ibrutinib on the cell viability of MYD88 L265P-bearing BCWM.1 and MWCL-1 WM cells, and OCI-Ly3 DLBCL cells vs MYD88 WT-expressing Ramos, OCI-Ly19, and RPMI 8226.

MYD88 signals through BTK in response to TLR stimulation, and BTK is stimulated by MYD88 L265P in WM cells. (A) The impacts of TLR4 ligand, LPS, and TLR9 ligand, ODN 2006 (a type B CpG oligonucleotide; InvivoGen), on the phosphorylation of BTK and IκBα in BCWM.1 WM cells in the presence or absence of a MYD88 inhibitor. (B) Total and phospho-BTK levels in WM cells transduced with a lentiviral control vector, or vectors engineered to overexpress flag-tagged MYD88 WT or L265P coding regions. (C) The impact of ibrutinib on the phosphorylation state of BTK and IκBα depicted by western blot analysis. (D) Dose-response curve for ibrutinib on the cell viability of MYD88 L265P-bearing BCWM.1 and MWCL-1 WM cells, and OCI-Ly3 DLBCL cells vs MYD88 WT-expressing Ramos, OCI-Ly19, and RPMI 8226.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal